Prologue

Prologue Medicines is a biotechnology company launched by Flagship Pioneering in 2024 to explore the therapeutic potential of the viral proteome. The company utilizes its proprietary DELVE (Decoding Evolutionary Logic of Variant Ensembles) platform to systematically map and decode the vast array of proteins encoded by viruses. By leveraging the evolutionary wisdom of viruses, which have spent billions of years developing ways to modulate human biology, Prologue aims to discover novel medicines for a wide range of diseases. The company's initial focus includes developing protein and peptide-based therapies for immunology, oncology, and metabolic disorders. Headquartered in Cambridge, Massachusetts, Prologue represents a new frontier in drug discovery by treating the virome as a rich source of bioactive molecules.